Clinical trials: Supranuclear Palsy, Progressive
Healthy Volunteers, Alzheimer Disease
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET
The overall goal of this protocol is to evaluate [18F]MNI-958 also known as APN-0000455 or PM-PBB3, a tau targeted radiopharmaceutical.
- Conditions
- Healthy Volunteers, Alzheimer Disease, Progressive Supranuclear Palsy
- Trial name
- NCT03545789
- Testing
- [18F]MNI-958
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Invicro
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Neurodegenerative Diseases, Alzheimer Disease
Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study
In this retrospective register study, clinically classified individuals with neurodegenerative disease from the years 2010-2021 will be verified from the clinical records from KUH and Oulu University Hospital (OUH).
- Conditions
- Neurodegenerative Diseases, Alzheimer Disease, Frontotemporal Dementia, Lewy Body Disease
- Trial name
- DEGERWD (NCT06209515)
- Where
- Finland
- Volunteers
- 61,292 people
- Sponsor
- Kuopio University Hospital
Progressive Supranuclear Palsy
Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks
This is a 12-week study of oral tolfenamic acid vs. placebo in Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04253132
- Testing
- Tolfenamic Acid
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NeuroTau, Inc.
Multiple System Atrophy, Progressive Supranuclear Palsy (PSP)
Synaptic Loss in Multiple System Atrophy
In this study the investigators would like to investigate the degree of damage of the synapses, an important part of the neurons vital for the communications between neurons, in Multiple System Atrophy (MSA), and pathology…
- Trial name
- NCT05121012
- Testing
- Study procedures for MSA patients, Study procedures for PSP patients
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- University of Exeter
Progressive Supranuclear Palsy
Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy
The study will enroll 20 PSP and 8 normal subjects with complete neurological examination, 18F-PMPBB3 (APN-1607) PET and MRI assessment.
- Trial name
- NCT04541836
- Testing
- 18F-PMPBB3
- Where
- Taiwan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Parkinson Disease, Multiple System Atrophy
Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging
The goals of this study are: 1) to identify biomarkers using neuroimaging that are associated with progression rate using statistical methods, and 2) to identify biomarkers that are associated with the differential diagnosis of…
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- NCT03872102
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Alzheimer Disease, Mild Cognitive Impairment
Tau Imaging With JNJ067
This protocol is designed to assess the utility of a new positron emission tomography (PET) radiopharmaceutical to image tau, [18F] JNJ067, invented by Janssen Pharmaceutical companies of Johnson \& Johnson.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Progressive Supranuclear Palsy
- Trial name
- NCT03926702
- Testing
- Radiopharmaceuticals
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Parkinson's Disease, Multiple System Atrophy
Magnetic Resonance Imaging in the Diagnosis of Parkinsonian Syndromes
Parkinsonian syndrome is clinically characterized by the presence of resting tremor, rigidity, bradykinesia and postural instability.
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, Vascular Parkinsonism
- Trial name
- PARKIMAGE (NCT02445469)
- Testing
- MRI exam of the brain
- Where
- France
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Tauopathies
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain…
- Trial name
- NCT06932809
- Testing
- 18F-JSS20-183A PET, Brain MRI, Amyloid PET
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Pennsylvania
Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP)
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
The overall goal of this imaging trial is to characterize [18F]MNI-815, a PET radioligand for imaging Tau.
- Conditions
- Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS), Frontal Temporal Dementia (FTD)
- Trial name
- NCT02531360
- Testing
- [18F]MNI-815 (MNI-815)
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Progressive Supranuclear Palsy
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
The purpose of the study is to evaluate the safety and efficacy of davunetide for the treatment of Progressive Supranuclear Palsy.
- Trial name
- NCT01110720
- Testing
- Davunetide
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 313 people
- Sponsor
- Allon Therapeutics
Parkinsonian Syndromes, Parkinson's Disease
Biomarkers in Parkinsonian Syndromes
Parkinson disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are neurodegenerative disorders. PD and MSA are alpha-synucleinopathies, which are characterized by the abnormal accumulation of…
- Conditions
- Parkinsonian Syndromes, Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- BIOPARK (NCT02114242)
- Testing
- CSF, blood and urine sampling, clinical measures of disease severity and progression
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
Geriatric, Parkinsons Disease (PD)
Collection of Digital Parameters From Parts of the Neurological Examination Using an Eye Tracker
The neurological examination (NE) is a cornerstone of clinical neurology, with ocular motor assessment being a key component. Technology offers an opportunity to augment and standardize parts of the NE.
- Conditions
- Geriatric, Parkinsons Disease (PD), Progressive Supranuclear Palsy(PSP), Neurological Diseases or Conditions
- Trial name
- NEX-Eye (NCT07141719)
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- University of Kiel
Progressive Supranuclear Palsy (PSP)
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
The purpose of this study was to assess the long-term safety and efficacy of ABBV-8E12 (tilavonemab) in participants with progressive supranuclear palsy (PSP).
- Trial name
- NCT03391765
- Testing
- ABBV-8E12
- Where
- 42 sites in United States, Australia and 3 more
- Volunteers
- 142 people
- Sponsor
- AbbVie
Alzheimer's Disease, Dementia
Diagnosis and Natural History Study of Patients With Neurological Conditions
The purpose of this study is to improve understanding of neurological conditions. Patients participating in this study will continue receiving medical care, routine laboratory tests, and diagnostics tests (X-rays, CT-scans, and…
- Conditions
- Alzheimer's Disease, Dementia, Movement Disorder, Multiple System Atrophy
- Trial name
- NCT00001549
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Alzheimer Disease, Progressive Supranuclear Palsy
Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity
This is an open-label study without randomisation. All eligible patients will receive two administrations of the investigational imaging agent [18F]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg…
- Trial name
- NCT04715750
- Testing
- [18F]-PI2620
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Life Molecular Imaging GmbH
Supranuclear Palsy, Progressive
Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003
The purpose of this study is to evaluate the long-term safety and tolerability of multiple intravenous (IV) infusions of BIIB092 in participants with Progressive Supranuclear Palsy (PSP).
- Trial name
- NCT02658916
- Testing
- BIIB092
- Where
- 13 sites in United States
- Volunteers
- 47 people
- Sponsor
- Biogen
Parkinson's Disease, Parkinsonian Syndrome
Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes
The purpose of the study is to determine the sensitivity and specificity of transcranial duplex scanning (TCD) and single photon emission computer tomography (SPECT) in patients suspected of having Idiopathic Parkinson Disease…
- Conditions
- Parkinson's Disease, Parkinsonian Syndrome, Multiple System Atrophy, Supranuclear Palsy, Progressive
- Trial name
- NCT00368199
- Where
- Netherlands
- Volunteers
- 196 people
- Sponsor
- Maastricht University Medical Center
Parkinson Disease, Multiple System Atrophy
Evaluation of the Efficacy of a Two-week EMST on Dysphagia in Parkinsonian Patients
This is an interventional therapy study designed to evaluate the efficacy of a two-week intervention, i.e. training with a specialized exhalation training device (called expiratory muscle strength training; EMST150 or EMST75…
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- EMST-PS (NCT05139342)
- Testing
- expiratory muscle strentgh training (EMST)
- Where
- 3 sites in Germany
- Volunteers
- 75 people
- Sponsor
- Kliniken Beelitz GmbH